Special Issue "Theranostic Drug Delivery: Prospects and Problems"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Biomedical Materials and Nanomedicine".

Deadline for manuscript submissions: 31 May 2021.

Special Issue Editor

Prof. Dr. M. R. Mozafari
Website
Guest Editor
Monash University, Melbourne, Australia
Interests: nanoBiotechnology; drug delivery; pharmaceutics; molecular biology; liposomes; drug targeting; cancer; pharmaceutical nanotechnology

Special Issue Information

Dear Colleagues,

Theranostic drug delivery exploits the combined properties of diagnosis and therapy and as such can benefit the development of targeted drug delivery systems and modern personalized medicine. The theranostic approach is used to design and formulate biocompatible and smart protocols for controlled, stimuli-responsive gene or drug delivery for various applications. It is expected that the success of theranostics will depend on multidisciplinary efforts, combined to expedite our understanding of host responses to customized theranostic agents and formulating individualized therapies. This Special Issue aims to provide an up-to-date collection of original research articles and review papers on the development of novel targeted drug delivery systems for the encapsulation and delivery of chemotherapeutic reagents, DNA- and RNA-based molecules, peptides, and other bioactive compounds. The themed issue will encompass significant efforts aimed at using biological language to discern between “friends” and “foes” in the context of theranostics for accurate clinical applications.

Prof. M. R. Mozafari
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • controlled release
  • diagnosis
  • drug carrier
  • drug delivery
  • drug targeting
  • encapsulation
  • nanotherapy
  • personalized medicine
  • theranostics

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle
Rational Design of Albumin Theranostic Conjugates for Gold Nanoparticles Anticancer Drugs: Where the Seed Meets the Soil?
Biomedicines 2021, 9(1), 74; https://doi.org/10.3390/biomedicines9010074 - 13 Jan 2021
Abstract
Multifunctional gold nanoparticles (AuNPs) may serve as a scaffold to integrate diagnostic and therapeutic functions into one theranostic system, thereby simultaneously facilitating diagnosis and therapy and monitoring therapeutic responses. Herein, albumin-AuNP theranostic agents have been obtained by conjugation of an anticancer nucleotide trifluorothymidine [...] Read more.
Multifunctional gold nanoparticles (AuNPs) may serve as a scaffold to integrate diagnostic and therapeutic functions into one theranostic system, thereby simultaneously facilitating diagnosis and therapy and monitoring therapeutic responses. Herein, albumin-AuNP theranostic agents have been obtained by conjugation of an anticancer nucleotide trifluorothymidine (TFT) or a boron-neutron capture therapy drug undecahydro-closo-dodecaborate (B12H12) to bimodal human serum albumin (HSA) followed by reacting of the albumin conjugates with AuNPs. In vitro studies have revealed a stronger cytotoxicity by the AuNPs decorated with the TFT-tagged bimodal HSA than by the boronated albumin conjugates. Despite long circulation time, lack of the significant accumulation in the tumor was observed for the AuNP theranostic conjugates. Our unique labelling strategy allows for monitoring of spatial distribution of the AuNPs theranostic in vivo in real time with high sensitivity, thus reducing the number of animals required for testing and optimizing new nanosystems as chemotherapeutic agents and boron-neutron capture therapy drug candidates. Full article
(This article belongs to the Special Issue Theranostic Drug Delivery: Prospects and Problems)
Show Figures

Graphical abstract

Review

Jump to: Research

Open AccessReview
Controlling Antibiotic Release from Polymethylmethacrylate Bone Cement
Biomedicines 2021, 9(1), 26; https://doi.org/10.3390/biomedicines9010026 - 01 Jan 2021
Abstract
Bone cement is used as a mortar for securing bone implants, as bone void fillers or as spacers in orthopaedic surgery. Antibiotic-loaded bone cements (ALBCs) have been used to prevent and treat prosthetic joint infections by providing a high antibiotic concentration around the [...] Read more.
Bone cement is used as a mortar for securing bone implants, as bone void fillers or as spacers in orthopaedic surgery. Antibiotic-loaded bone cements (ALBCs) have been used to prevent and treat prosthetic joint infections by providing a high antibiotic concentration around the implanted prosthesis. High antibiotic concentrations are, on the other hand, often associated with tissue toxicity. Controlling antibiotic release from ALBCS is key to achieving effective infection control and promoting prosthesis integration with the surrounding bone tissue. However, current ALBCs still need significant improvement in regulating antibiotic release. In this review, we first provide a brief introduction to prosthetic joint infections, and the background concepts of therapeutic efficacy and toxicity in antibiotics. We then review the current state of ALBCs and their release characteristics before focusing on the research and development in controlling the antibiotic release and osteo-conductivity/inductivity. We then conclude by a discussion on the need for better in vitro experiment designs such that the release results can be extrapolated to predict better the local antibiotic concentrations in vivo. Full article
(This article belongs to the Special Issue Theranostic Drug Delivery: Prospects and Problems)
Show Figures

Figure 1

Open AccessReview
Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus
Biomedicines 2020, 8(12), 580; https://doi.org/10.3390/biomedicines8120580 - 07 Dec 2020
Abstract
The outbreak of a novel strain coronavirus as the causative agent of COVID-19 pneumonia, first identified in Wuhan, China in December 2019, has resulted in considerable focus on virulence abilities of coronavirus. Lectins are natural proteins with the ability to bind specific carbohydrates [...] Read more.
The outbreak of a novel strain coronavirus as the causative agent of COVID-19 pneumonia, first identified in Wuhan, China in December 2019, has resulted in considerable focus on virulence abilities of coronavirus. Lectins are natural proteins with the ability to bind specific carbohydrates related to various microorganisms, including viruses, bacteria, fungi and parasites. Lectins have the ability to agglutinate and neutralize these pathogeneses. The delivery of the encapsulated antiviral agents or vaccines across the cell membrane can be possible by functionalized micellar and liposomal formulations. In this mini-review, recent advances and challenges related to important lectins with inhibition activities against coronaviruses are presented to obtain a novel viewpoint of microformulations or nanoformulations by micellar and liposomal cell-binding carriers. Full article
(This article belongs to the Special Issue Theranostic Drug Delivery: Prospects and Problems)
Show Figures

Figure 1

Back to TopTop